Shattuck Labs (STTK) reported second-quarter 2026 financial results and recent business updates, including Phase 1 clinical trial results for SL-325 and plans to start the RECEPTIVE-CD1 Phase 2b trial in Crohn’s disease in the third quarter of 2026.
The company reported $208.3 million in cash, cash equivalents and short-term investments as of June 30, 2026, which it expects to fund operations into 2029.
- Net loss was $15.2 million for the quarter ended June 30, 2026, or $0.12 per basic and diluted share.
- Revenue was $0 for the second quarter of 2026.
- R&D expenses were $11.7 million, compared with $8.7 million a year earlier.
- G&A expenses were $4.5 million, compared with $4.4 million a year earlier.
- SL-325 Phase 1 results showed a favorable safety profile, 3.7% antidrug antibody rate and durable DR3 blockade of TL1A binding.
- The SL-325 RECEPTIVE-CD1 Phase 2b Crohn’s disease trial is expected to begin in the third quarter of 2026, with primary endpoint data expected in the first half of 2028.
- Shattuck announced SL-846, a DR3 x IL-23 receptor blocking bispecific antibody, with initial Phase 1 clinical data expected in 2027.
- The company completed an underwritten public offering with approximately $86.2 million in gross proceeds, and warrant exercises generated approximately $57.1 million in gross proceeds.
$STTK Insider Trading Activity
$STTK insiders have traded $STTK stock on the open market 7 times in the past 6 months. Of those trades, 1 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $STTK stock by insiders over the last 6 months:
- ARUNDATHY N. PANDITE (Chief Medical Officer) has made 0 purchases and 2 sales selling 60,000 shares for an estimated $408,600.
- CLAY B SIEGALL purchased 62,500 shares for an estimated $250,000
- ABHINAV A. SHUKLA (Chief Technical Officer) has made 0 purchases and 4 sales selling 25,907 shares for an estimated $183,249.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$STTK Hedge Fund Activity
We have seen 57 institutional investors add shares of $STTK stock to their portfolio, and 22 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 3,425,004 shares (+670.5%) to their portfolio in Q2 2026, for an estimated $23,769,527
- PROSIGHT MANAGEMENT, LP added 2,622,937 shares (+110.1%) to their portfolio in Q1 2026, for an estimated $16,865,484
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,661,170 shares (-26.3%) from their portfolio in Q1 2026, for an estimated $10,681,323
- BANK OF AMERICA CORP /DE/ removed 1,026,693 shares (-92.8%) from their portfolio in Q1 2026, for an estimated $6,601,635
- STATE STREET CORP added 762,626 shares (+289.1%) to their portfolio in Q2 2026, for an estimated $5,292,624
- 683 CAPITAL MANAGEMENT, LLC removed 590,000 shares (-42.4%) from their portfolio in Q1 2026, for an estimated $3,793,700
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 567,538 shares (+382.4%) to their portfolio in Q1 2026, for an estimated $3,649,269
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
